title: Approach to and treatment of differentiated thyroid carcinoma.
abstract: Thyroid cancer is the most common endocrine malignancy, although representing fewer than 1% of all human tumors. Differentiated thyroid carcinoma (DTC) includes the papillary and follicular histotypes and their variants, accounting for more than 90% of all thyroid cancers. Given the changing presentation of DTC in the last years, the aim of DTC management is to ensure the most effective but least invasive treatment, and adequate follow-up for a disease that nowadays is mostly cured just with surgery and is rarely fatal. This review addresses the multiple steps of current management, based on previous assumptions.
authors.affiliation: Section of Endocrinology and Metabolism, Department of Internal Medicine, Endocrinology & Metabolism and Biochemistry, University of Siena, Policlinico Santa Maria alle Scotte, VialeBracci 1, 53100 Siena, Italy. pacini8@unisi.it
authors.forename: Furio
authors.initials: F
authors.lastname: Pacini
authors.forename: Maria Grazia
authors.initials: MG
authors.lastname: Castagna
mesh_terms: D018263:Adenocarcinoma, Follicular; D002277:Carcinoma; D002291:Carcinoma, Papillary; D002454:Cell Differentiation; D003131:Combined Modality Therapy; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D009367:Neoplasm Staging; D018570:Risk Assessment; D016019:Survival Analysis; D000077273:Thyroid Cancer, Papillary; D013961:Thyroid Gland / Q000473:pathology / Q000528:radiation effects / Q000601:surgery; D013964:Thyroid Neoplasms / Q000175:diagnosis / Q000473:pathology* / Q000628:therapy*; D013965:Thyroidectomy / Q000379:methods; D013974:Thyroxine / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D007457:Iodine Radioisotopes; D013974:Thyroxine